Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 703.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,792 shares of the biotechnology company’s stock after purchasing an additional 16,453 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Anavex Life Sciences were worth $161,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Vermillion Wealth Management Inc. acquired a new stake in shares of Anavex Life Sciences in the fourth quarter valued at about $34,000. Tower Research Capital LLC TRC grew its position in shares of Anavex Life Sciences by 102.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 1,708 shares during the period. 180 Wealth Advisors LLC acquired a new stake in shares of Anavex Life Sciences in the first quarter valued at about $121,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Anavex Life Sciences in the first quarter valued at about $141,000. Finally, Yukon Wealth Management Inc. acquired a new stake in shares of Anavex Life Sciences in the first quarter valued at about $147,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Trading Down 1.2%

NASDAQ:AVXL opened at $11.08 on Monday. The company’s 50-day moving average price is $10.07 and its 200-day moving average price is $9.18. The company has a market cap of $946.45 million, a P/E ratio of -20.15 and a beta of 0.80. Anavex Life Sciences Corp. has a twelve month low of $4.93 and a twelve month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same quarter in the previous year, the company earned ($0.13) earnings per share. On average, analysts expect that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analysts Set New Price Targets

Separately, D. Boral Capital reissued a “buy” rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research note on Monday, August 4th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.